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Abstract 
Purpose: to summarise the results of recent Cochrane systematic reviews that have investigated 
whether nutritional supplements prevent or slow the progression of AMD.  
Recent findings: there is no good evidence from randomised controlled trials (RCTs) that the general 
population should be taking antioxidant vitamin supplements to reduce their risk of developing AMD 
later on in life. By contrast, there is moderate quality evidence that people with AMD may 
experience a delay in progression by taking specific antioxidant vitamin and mineral supplements. 
This finding is drawn from one large RCT conducted in the USA in a relatively well-nourished 
population. Although observational studies have shown that the consumption of dietary omega 3 
long chain polyunsaturated fatty acids (LCPUFA) may reduce the risk of progression to advanced 
AMD, two recently published RCTs failed to show any benefit of omega 3 supplements on AMD 
progression. 
Summary: there is no high quality experimental evidence that nutritional supplementation is 
beneficial for the primary prevention of AMD. However, people with AMD may benefit from 
supplementation with antioxidant vitamins. There is currently no evidence to support increasing 
levels of omega 3 LCPUFA in the diet for the explicit purpose of preventing or slowing the 
progression of AMD.  
 
Background 
Age-related macular degeneration (AMD) accounts for over 50% of blind and partially sighted 
registrations in the UK(1), and with an ageing population the prevalence of the disease is predicted 
to rise exponentially, with an estimated 679,000 cases of late AMD by 2020(2). In addition to the 
obvious personal impact of AMD, the societal burden is substantial. Economic costs arise from both 
the direct costs of treatment as well as indirect costs associated with visual impairment, including 
the provision of social care(3). The cumulative direct and indirect cost for the UK over the decade 
2010 to 2020 has been estimated to be more than £16.4 billion(4).  
Although effective treatments in the form of vascular endothelial growth factor inhibitors are 
available that can slow the progression of the neovascular form of the disease, there is still no 
effective treatment for atrophic AMD, which affects the majority of AMD sufferers. It is likely that 
the pathogenesis of AMD is multi-factorial, arising from a complex interplay between genetic and 
environmental factors. Significantly, a number of gene polymorphisms have been identified which 
appear to iŶĐrease aŶ iŶdiǀidual͛s susĐeptiďilitǇ to eŶǀiroŶŵeŶtal risk faĐtors (reǀieǁed iŶ DiŶg et 
al(5)). Smoking has been consistently reported as a major risk factor for AMD. Current smoking 
increases the risk of AMD approximately two-fold(6) and the finding of a dose-response relationship 
ďetǁeeŶ the Ŷuŵďer of ͚paĐk Ǉears͛ sŵoked aŶd a loǁer risk iŶ past sŵokers ǁould suggest that 
smoking cessation may be an effective strategy for AMD prevention and control. The role of diet and 
nutrition has also attracted significant interest. Observational studies have reported that particular 
dietary components such as omega-3 fatty acids, carotenoids, antioxidant vitamins or diets with a 
lower glycaemic index can reduce the risk of developing AMD or slow its progression (see (7) for a 
recent review). However, these results from non-experimental studies should always be interpreted 
with caution, since people with a diet rich in particular nutrients may differ in other ways from those 
who do not. Nonetheless, these data have been used as the basis for promoting nutritional 
supplements for eye health, which contain high doses of specific micronutrients. These products are 
targeted at the general population and are also widely recommended by eye healthcare 
professionals for people who have signs of AMD(8). The aim of this review is to summarise the 
results of recent Cochrane systematic reviews that have specifically investigated whether nutritional 
supplements prevent or slow the progression of AMD. The review will also consider the risk of 
adverse effects associated with these supplements.
  
Antioxidant vitamin and mineral supplements  
The ͞free radiĐal theorǇ of ageiŶg͟ proposes that the rate of ageiŶg is, iŶ part, deterŵiŶed ďǇ the 
ability of organisms to deal with the harmful effects of metabolites of molecular oxygen, known as 
reactive oxygen species or free radicals (reviewed in (9)). AMD is an age-related degenerative 
condition. The retina is thought to be under oxidative stress due to the action of light on the 
photoreceptors which generate free radicals. The hypothesis is that AMD develops, in part, because 
of the cumulative effects of oxidative stress and that antioxidants may be important in its prevention 
(reviewed in (10)).  
There are two key questions: should the general population take antioxidant supplements to reduce 
the risk of developing AMD later on in life (primary prevention) or should people with AMD take 
antioxidant supplements to slow down the progression of the disease (secondary prevention).   
Primary prevention 
The CoĐhraŶe reǀieǁ ͞AŶtioǆidaŶt ǀitaŵiŶ aŶd ŵiŶeral suppleŵeŶts for preǀeŶtiŶg age-related 
ŵaĐular degeŶeratioŶ͟ ǁas last updated in 2012(11). The review includes four trials that randomised 
62,520 people in total. The trials were conducted in Australia, Finland and the USA and investigated 
vitamin E and beta-carotene supplements. Overall the quality of the evidence was high. People who 
took these supplements were not at decreased (or increased) risk of developing AMD. The pooled 
risk ratio for any antioxidant supplement in the prevention of any AMD was 0.98 (95% confidence 
interval (CI) 0.89 to 1.08) (Figure 1). 
  
Figure 1.  Forest plot of trials comparing the effect of antioxidant vitamins on the development of any AMD. In 
this meta-analysis a fixed effects approach was used and the weighted risk ratios were calculated using the 
Mantel-Haenszel (M-H) method. 
There were fewer cases of advanced AMD and the estimate of effect was therefore less certain 1.05 
(95% CI 0.80 to 1.39) (Figure 2) however there is little support for the hypothesis that these 
supplements prevent the development of AMD. Similar results were seen when the analyses were 
done separately for beta-carotene and vitamin E.  
Since this review was last updated the results of the Physicians Health Study (PHS) II have been 
published(12). The PHS II evaluated a daily multivitamin supplement, Centrum Silver, which includes 
antioxidant vitamins (A, C, E, zinc and lutein) as well as a number of other vitamins and minerals (for 
a full list of ingredients see (13)). PHS II was set up to evaluate the effects on prevention of cancer 
and CVD but cataract and AMD were pre-specified secondary end points. AMD was determined by 
self-report confirmed by medical record review. A total of 14,641 US male physicians took 
supplements for an average of 11 years and 281 cases of visually significant AMD were identified 
during that time (152 cases in the multivitamin group and 129 cases in the placebo group). There 
was no evidence of any protective effect of this multivitamin supplement on development of AMD 
(hazard ratio§ 1.19; 95% CI 0.94 to 1.50). This trial will be included in the next update of the 
Cochrane review.  
 
Figure 2.  Forest plot of trials comparing the effect of antioxidant vitamins on the development of advanced 
AMD 
In summary, there is good evidence that taking vitamin E or beta-carotene supplements will not 
prevent or delay the onset of AMD. Furthermore, there is no evidence from randomised controlled 
trials that other antioxidant supplements, such as vitamin C, lutein and zeaxanthin, or any of the 
commonly marketed multivitamin combinations will prevent the development of AMD.  
Secondary prevention 
The CoĐhraŶe reǀieǁ ͞AŶtioǆidaŶt ǀitaŵiŶ aŶd ŵiŶeral suppleŵeŶts for sloǁiŶg the progressioŶ of 
age-related macular degeŶeratioŶ͟ ǁas also last updated iŶ ϮϬϭϮ(ϭ4). Compared to the primary 
prevention review, a larger number of trials were included (n=13) but these were in general smaller 
with a total of 6,150 participants. Over half the participants (3,640) were randomised in one trial, 
AREDS in the USA(15), which found a beneficial effect of antioxidant (beta-carotene, vitamin C and 
vitamin E) and zinc supplementation on progression to advanced AMD (adjusted odds ratio (OR) 
0.68, 95% CI 0.53 to 0.87) over an average of 6.3 years. People taking supplements were less likely to 
lose 15 or more letters of visual acuity (adjusted OR 0.77, 95% CI 0.62 to 0.96). The other trials, in 
general, had shorter follow-up (less than two years). No evidence for an effect of supplementation 
was seen in these smaller trials of shorter duration. Overall we considered the quality of the 
evidence to be moderate. The main reason for downgrading the assessment of quality was because, 
for several analyses, only one trial was included and therefore consistency of the findings could not 
be assessed.  
Since the review was last updated, the results of AREDS2 have been published (16). In AREDS2 
participants took the AREDS supplement (or a variation of) and were randomly assigned to either 
omega 3 fatty acids supplements or lutein/zeaxanthin. The study was a factorial design.  A total of 
4,203 people who had bilateral large drusen or large drusen in one eye and advanced AMD in the 
fellow eye were followed up for 5 years. The primary analysis found that the addition of lutein and 
zeaxanthin to the original supplement did not have any detectable effect on progression to 
advanced AMD (hazard ratio 0.90, 98.7% CI 0.76 to 1.07). However, the authors did some further 
exploratory analyses on the trial data by comparing those taking and not taking lutein/zeaxanthin 
(17). These analyses suggested that lutein and zeaxanthin may be a better component of the AREDS 
formula substituting beta-carotene. AREDS2 will be included in the next update of the Cochrane 
review.  
Adverse effects of antioxidant vitamin supplements 
Although generally regarded as safe, vitamin supplements, particularly if high dose, may have 
harmful effects.  Trials, particularly if they are small in size, may not be the best way to assess 
adverse effects because important adverse effects may occur rarely and trials are usually not large 
enough to measure rare outcomes.  
In the trials of antioxidant vitamins and minerals the best evidence on adverse effects comes from 
AREDS. The main adverse effect of note was that people taking high-dose zinc were at increased risk 
of hospital admission due to genitourinary diseases (11.1% versus 7.6% P = 0.0003) (18).  
The issue of adverse effects has been studied in larger trials for other medical conditions. The ATBC 
trial found an increased risk of lung cancer associated with beta-carotene supplementation(19), a 
finding that was repeated in the large CARET trial(25). As a result of the evidence from these trials, 
people who smoke or have been exposed to asbestos, are advised not to take beta-carotene. 
For the last update of the Cochrane reviews on antioxidant vitamins supplements we did a search for 
reviews of adverse effects. One review did not identify any consistent adverse effects of mineral and 
vitamin supplements but only included nine RCTs (20). A Cochrane Review investigating antioxidant 
supplements for preventing all-cause mortality, including 78 trials with 296,707 participants, 
concluded "We found no evidence to support antioxidant supplements for primary or secondary 
prevention. Beta-carotene and vitamin E seem to increase mortality, and so may higher doses of 
vitamin A" (21). 
  
Omega 3 fatty acids  
Primary and secondary prevention 
There is a plausible biological rationale for increasing dietary omega 3 fats in AMD. The omega 3 
fatty acid docosahexaenoic acid (DHA) accounts for 50% to 60% of the total fatty acid content of the 
outer segments of photoreceptors. The constant turnover of outer segment membranes requires a 
continuous dietary supply of DHA or its precursors and a deficiency may predispose to the 
development of AMD. Furthermore, omega 3 LCPUFA may also confer protection against the 
oxidative, inflammatory and vasogenic processes that play a key role in the pathogenesis of AMD(22, 
23). Observational studies in humans have reported that the consumption of fish or foods rich in 
omega 3 long-chain polyunsaturated fatty acids (LCPUFA) could reduce the risk of developing 
AMD(24-27). Similarly, a nested cohort study within the Age-Related Eye Disease Study (AREDS) 
found that participants at moderate to high risk of progressing to late AMD, who reported the 
highest consumption of omega 3 LCPUFA, were 30% less likely to develop geographic atrophy and 
neovascular AMD when compared to those reporting the lowest consumption(28).  
Two randomised controlled trials that specifically investigated whether omega 3 LCPUFA 
supplementation could decrease the risk of developing advanced AMD were recently published (17, 
29). In the Age-related Eye Disease Study 2 (AREDS2), 2080 people aged 50-85, at high risk of 
progressing to advanced AMD, were randomised to receive a daily dose of DHA (350mg) (N=1068) 
and eicosapentaenoic acid (EPA) (650mg) or a control supplement (N=1012). The median follow up 
period was 5 years. In the Nutritional AMD Treatment 2 (NAT-2) study, 263 people aged 55-85 were 
randomly assigned to receive 840 mg of DHA and 270 mg EPA per day or a placebo for a period of 3 
years. In both trials, the main outcome measures were the development of advanced AMD and 
progression to moderate or worse vision loss (defined as a loss of 15 or more letters on a standard 
EDTRS chart). The trials, which had a low risk of bias, provided high quality evidence that people 
taking omega 3 LCPUFA supplements were not at a decreased (or increased) risk of developing 
advanced AMD. The pooled hazard ratio for progression of AMD (Figure 3) was 0.96 (95% CI 0.84 to 
1.10).  
 Figure 3.  Forest plot of trials comparing the effect of omega 3 fatty acids on progression of AMD. In this meta-
analysis the weight assigned to each study is based on the inverse of its variance (IV method). 
People taking supplements were similarly no more (or less) likely to lose 15 or more letters of visual 
acuity (AREDS 2: hazard ratio 0.96 (95% CI, 0.84-1.09); NAT-2 odds ratio 1.15 (95% CI 0.67 to 1.99). 
No clinically or statistically significant differences in serious adverse outcomes were reported across 
treatment groups.  
Conclusions and future directions  
Vitamin supplements, which are widely marketed and consumed by the general population, may 
have harmful effects. For example, two large trials found an increased risk of lung cancer associated 
with beta-carotene supplementation. For this reason, it is important to ensure that there is good 
evidence to support the use of vitamin supplements for either primary or secondary prevention of 
AMD. Based on the results from RCTs, there is currently no good evidence that the general 
population should take any of the commonly marketed nutritional supplements to prevent the 
development of AMD. By contrast, people with AMD may experience a modest delay in progression 
of the disease with specific antioxidant vitamin and mineral supplementation. This finding is drawn 
from one large RCT conducted in the USA in a relatively well-nourished population(15). The recently 
published AREDS2 trial (17) reported that the addition of the carotenoids lutein and zeaxanthin to 
the original supplement did not provide any further benefit.  
A critique of the current literature on whether or not people with AMD should take antioxidant 
supplements is that recommendations are primarily based on the results of one study – the AREDS 
study in the USA. Although other trials have been done they have generally been small and of short 
duration with inconclusive results. Further large scale and simple randomised controlled trials need 
to be done in this area. Trialists need to report an agreed core set of outcomes to enable the results 
of studies to be combined in systematic reviews (30). The use of nutritional supplements is an 
important question and better evidence supporting their use in patients with AMD is needed.  
 Although observational studies have shown that the consumption of omega 3 LCPUFA may confer 
protection against AMD and reduce the risk of progression to advanced AMD, this is not supported 
by published RCTs, which have failed to show any benefit of omega 3 supplements on progression to 
advanced AMD. Therefore, there is currently no high quality evidence to support increasing levels of 
omega 3 LCPUFA in the diet for the explicit purpose of preventing or slowing the progression of 
AMD. 
 
The data presented in this review were based only on RCTs where single micronutrients or particular 
combinations of antioxidants were compared to placebo. These trials do not address the overall 
impact of the diet on the development or progression of AMD. The role of diet may be complex, and 
it is possible that dietary patterns are important (31). Randomised controlled trials may not be a 
feasible study design for testing the effects of dietary patterns and therefore data from 
observational (non-randomised) studies will need to be used. The interpretation of observational 
studies can be problematic since these study designs are more prone to bias and confounding. There 
is a need for a regularly updated systematic review of the evidence from good quality prospective 
cohort studies, where researchers have attempted to control for known confounders, to add to the 
evidence base for the association between diet and AMD. 
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